UBS Downgrades Avon Products (AVP) to Neutral; Ding Dong - No One’s Home
Get Alerts AVP Hot Sheet
Price: $5.60 --0%
Rating Summary:
3 Buy, 12 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 12
Rating Summary:
3 Buy, 12 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 12
Join SI Premium – FREE
UBS downgraded Avon Products (NYSE: AVP) from Buy to Neutral, price target slashes from $31 to $20.
UBS analyst says, "In retrospect, we should have adhered to our original downgrade thesis on AVP earlier in the year—poor execution would limit upside. As AVP shares sold off and investor sentiment soured, we believed there was a contrarian opportunity to buy the stock. We were wrong. Due to our major concerns in the company’s ability to execute, a full internal review of the company’s business model, two SEC investigations and a risk to the dividend, we are downgrading the stock." (UBS lowers FY 2012 numbers to $1.69 from $2.21)
For more ratings news on Avon Products click here and for the rating history of Avon Products click here.
Shares of Avon Products closed at $18.81 yesterday.
UBS analyst says, "In retrospect, we should have adhered to our original downgrade thesis on AVP earlier in the year—poor execution would limit upside. As AVP shares sold off and investor sentiment soured, we believed there was a contrarian opportunity to buy the stock. We were wrong. Due to our major concerns in the company’s ability to execute, a full internal review of the company’s business model, two SEC investigations and a risk to the dividend, we are downgrading the stock." (UBS lowers FY 2012 numbers to $1.69 from $2.21)
For more ratings news on Avon Products click here and for the rating history of Avon Products click here.
Shares of Avon Products closed at $18.81 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Telix Pharmaceuticals (TLX) Announces FDA Approval of Gozellix
- VivoPower (VVPR) Announces Tembo E-LV Progresses Business Combination Agreement with CCTS at a Combined Enterprise Value of $904m
- Heng Ren Partners Demands Sinovac (SVA) Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading
Create E-mail Alert Related Categories
DowngradesRelated Entities
UBS, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!